Laurens J Ceulemans1,2,3, Ilhan Inci3, Dirk Van Raemdonck1,2. 1. Department of Thoracic Surgery, University Hospitals Leuven. 2. Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium. 3. Department of Thoracic Surgery, University Hospital Zürich, Zürich, Switzerland.
Abstract
PURPOSE OF REVIEW: The current review presents a concise update on published literature on donation after circulatory death (DCD) and lung transplantation (LTx). Worldwide an increasing need for lungs is evident, however the utilization rate of DCD lung donors is still considerably low. In this summary article, we reviewed both the experimental background and international clinical experience. RECENT FINDINGS: Our analysis confirmed satisfactory results for LTx from DCD donors, which equals the results from donation after brain death. Although most studies reported on short-term results, some confirmed these results on the long-term and development of chronic lung allograft dysfunction. Our review summarizes the different DCD categories and underlines the potential of the DCD V category. We analyze the barriers to implement a DCD program, discuss the more recent advances like ex-vivo lung perfusion and describe the future challenges. SUMMARY: Based on the current short-term and long-term clinical results, we believe that barriers for DCD utilization should be overcome, resulting in a safe implementation of more DCD LTx programs worldwide. VIDEO ABSTRACT.
PURPOSE OF REVIEW: The current review presents a concise update on published literature on donation after circulatory death (DCD) and lung transplantation (LTx). Worldwide an increasing need for lungs is evident, however the utilization rate of DCD lung donors is still considerably low. In this summary article, we reviewed both the experimental background and international clinical experience. RECENT FINDINGS: Our analysis confirmed satisfactory results for LTx from DCD donors, which equals the results from donation after brain death. Although most studies reported on short-term results, some confirmed these results on the long-term and development of chronic lung allograft dysfunction. Our review summarizes the different DCD categories and underlines the potential of the DCD V category. We analyze the barriers to implement a DCD program, discuss the more recent advances like ex-vivo lung perfusion and describe the future challenges. SUMMARY: Based on the current short-term and long-term clinical results, we believe that barriers for DCD utilization should be overcome, resulting in a safe implementation of more DCD LTx programs worldwide. VIDEO ABSTRACT.
Authors: Beatriz Domínguez-Gil; Nancy Ascher; Alexander M Capron; Dale Gardiner; Alexander R Manara; James L Bernat; Eduardo Miñambres; Jeffrey M Singh; Robert J Porte; James F Markmann; Kumud Dhital; Didier Ledoux; Constantino Fondevila; Sarah Hosgood; Dirk Van Raemdonck; Shaf Keshavjee; James Dubois; Andrew McGee; Galen V Henderson; Alexandra K Glazier; Stefan G Tullius; Sam D Shemie; Francis L Delmonico Journal: Intensive Care Med Date: 2021-02-26 Impact factor: 17.440
Authors: Thomas M Egan; Benjamin E Haithcock; Jason Lobo; Gita Mody; Robert B Love; John Jacob Requard; John Espey; Mir Hasnain Ali Journal: J Thorac Dis Date: 2021-11 Impact factor: 3.005
Authors: Christopher M Bobba; Bryan A Whitson; Matthew C Henn; Nahush A Mokadam; Brian C Keller; Justin Rosenheck; Asvin M Ganapathi Journal: Transpl Int Date: 2022-04-04 Impact factor: 3.842